The fill rate of antibiotics for bacterial infections from respiratory syncytial virus surpassed the previous season's trend, indicating an unusually early RSV season. 

Surgeons and health system leaders are voicing concerns about the unknown long-term risks of glucagon-like peptide-1 receptor agonists, such as Ozempic, Wegovy and Saxenda. 

The FDA issued a final rule Nov. 21 that will require drugmakers to clearly state side effects and contraindications in direct-to-consumer advertisements. The rule is effective May 20, 2024. 

There's been a slight slowdown in reports of new drug shortages before the winter holiday season, but six medications recently entered the list of ongoing shortages, which include about 300 drugs. 

Seven senators are questioning why Sanofi and AstraZeneca underestimated the demand for Beyfortus, the first pediatric drug approved for respiratory syncytial virus. 

Timber Pharmaceuticals filed for Chapter 11 bankruptcy Nov. 17. 

Leigh Briscoe-Dwyer, PharmD, is mentoring the next generation of pharmacists as she pulls on her years of experience, according to a Nov. 17 article from Binghamton (N.Y.) University. 

The FDA approved CorMedix's Defencath Nov. 15, marking it the first and only catheter lock solution for catheter-related bloodstream infections. 

An FDA panel is urging Acrotech Biopharma to accelerate research into the efficacy of two blood cancer drugs brought to market via the agency's accelerated approval pathway.

In early 2023, the number of drug shortages hit a 10-year high. A fourth of these shortages are more than five years old, and 58% are older than two years, according to a new report.